[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626551":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":59,"collaborators":34,"id":61,"slug":34,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":34,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":34,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":34,"overallStatus":47,"whyStopped":34,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: Single Ascending Dose","EXPERIMENTAL","Participants will be randomized to receive a single dose of VX-272.",[13],"Drug: VX-272",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo: Part A","PLACEBO_COMPARATOR","Participants will be randomized to receive a single dose of placebo matched to VX-272.",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Part B: Multiple Ascending Dose","Participants will be randomized to receive multiple doses of VX-272.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Placebo: Part B","Participants will be randomized to receive multiple doses of placebo matched to VX-272.",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","VX-272","Suspension for Oral Administration.",[9,21],null,{"type":30,"name":36,"description":32,"armGroupLabels":37,"otherNames":34},"Placebo",[15,25],[39],{"name":40,"role":41,"phone":42,"phoneExt":34,"email":43},"Medical Information","CONTACT","617-341-6777","medicalinfo@vrtx.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":34},"Celerion - Tempe","RECRUITING","Tempe","Arizona","85283","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-111.90931,33.41477,{"lat":57,"lon":56},{"type":60,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100626551",false,"NCT07437105","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects","Key Inclusion Criteria:\n\n* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg\u002Fm\\^2)\n* A total body weight of more than (\\>) 50 kg\n* Male and Female participants of non-childbearing potential\n\nKey Exclusion Criteria:\n\n* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug\n* Any condition possibly affecting drug absorption\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",true,"ALL","18 Years","55 Years",{"count":72,"type":73},128,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.",[79],"Cystic Fibrosis","2026-03-25",{"date":82,"type":83},"2026-03-31","ACTUAL",{"date":85,"type":83},"2026-02-25",{"date":87,"type":73},"2027-03-23",{"name":5,"class":6},1]